Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
192 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Macular Edema - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Diabetic Macular Edema - Pipeline Review, H1 2016', provides an overview of the Diabetic Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema - The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects - The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Diabetic Macular Edema Overview 8 Therapeutics Development 9 Pipeline Products for Diabetic Macular Edema - Overview 9 Pipeline Products for Diabetic Macular Edema - Comparative Analysis 10 Diabetic Macular Edema - Therapeutics under Development by Companies 11 Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes 14 Diabetic Macular Edema - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Diabetic Macular Edema - Products under Development by Companies 19 Diabetic Macular Edema - Products under Investigation by Universities/Institutes 22 Diabetic Macular Edema - Companies Involved in Therapeutics Development 23 Aciont Inc. 23 ActiveSite Pharmaceuticals, Inc. 24 Acucela Inc. 25 Aerpio Therapeutics, Inc. 26 Allergan Plc 27 Ampio Pharmaceuticals, Inc. 28 Astellas Pharma Inc. 29 Avalanche Biotechnologies, Inc. 30 Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 31 Chong Kun Dang Pharmaceutical Corp. 32 EyeGate Pharmaceuticals, Inc. 33 EyeGene, Inc. 34 Gene Signal International SA 35 Genmab A/S 36 Icon Bioscience, Inc. 37 Kala Pharmaceuticals, Inc. 38 Kowa Company, Ltd. 39 Mabion SA 40 MacuCLEAR, Inc. 41 NicOx S.A. 42 Oculis ehf 43 Ohr Pharmaceutical Inc. 44 Quark Pharmaceuticals, Inc. 45 Regeneron Pharmaceuticals, Inc. 46 Santen Pharmaceutical Co., Ltd. 47 SciFluor Life Sciences, LLC 48 Senju Pharmaceutical Co., Ltd. 49 Shire Plc 50 Sucampo Pharmaceuticals, Inc. 51 ThromboGenics NV 52 Verseon Corporation 53 Xbrane Biopharma AB 54 Diabetic Macular Edema - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 59 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 (aflibercept + nesvacumab) - Drug Profile 65 abicipar pegol - Drug Profile 66 ACX-107 - Drug Profile 69 aganirsen - Drug Profile 70 AKB-9778 - Drug Profile 72 ALG-1001 - Drug Profile 74 Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 76 ASP-440 - Drug Profile 77 ASP-8232 - Drug Profile 79 ASPPDC-010 - Drug Profile 80 AVA-101 - Drug Profile 81 conbercept - Drug Profile 83 danazol - Drug Profile 85 dexamethasone acetate - Drug Profile 86 dexamethasone acetate - Drug Profile 88 dexamethasone dipropionate - Drug Profile 90 dexamethasone dipropionate XR - Drug Profile 91 difluprednate - Drug Profile 92 Drug for Diabetic Macular Edema - Drug Profile 94 Drugs to Inhibit Semaphorin 3A for Diabetic Macular Edema - Drug Profile 95 EG-Mirotin - Drug Profile 96 emixustat hydrochloride - Drug Profile 97 fluticasone propionate - Drug Profile 99 JDE-006 - Drug Profile 100 KVD-001 - Drug Profile 101 lanadelumab - Drug Profile 102 loteprednol etabonate - Drug Profile 103 MC-4001 - Drug Profile 105 methotrexate - Drug Profile 106 MTP-131 - Drug Profile 107 NCX-422 - Drug Profile 109 NCX-434 - Drug Profile 110 nesvacumab - Drug Profile 111 NM-108 - Drug Profile 113 OLX-303 - Drug Profile 114 PF-655 - Drug Profile 115 ranibizumab biosimilar - Drug Profile 118 ranibizumab biosimilar - Drug Profile 119 ranibizumab biosimilar - Drug Profile 120 RC-1 Alpha - Drug Profile 121 ripasudil - Drug Profile 122 RTU-1096 - Drug Profile 124 RX-10045 - Drug Profile 125 SF-0166 - Drug Profile 127 Small Molecule for Diabetic Macular Edema - Drug Profile 128 Small Molecule to Inhibit Kallikrein for DME - Drug Profile 129 Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile 130 squalamine lactate - Drug Profile 132 teprotumumab - Drug Profile 135 TG-758 - Drug Profile 138 TG-931 - Drug Profile 139 triamcinolone acetonide - Drug Profile 140 Diabetic Macular Edema - Recent Pipeline Updates 141 Diabetic Macular Edema - Dormant Projects 177 Diabetic Macular Edema - Discontinued Products 179 Diabetic Macular Edema - Product Development Milestones 180 Featured News & Press Releases 180 Appendix 187 Methodology 187 Coverage 187 Secondary Research 187 Primary Research 187 Expert Panel Validation 187 Contact Us 187 Disclaimer 188
List of Tables
Number of Products under Development for Diabetic Macular Edema, H1 2016 13 Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Development by Companies, H1 2016 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H1 2016 18 Comparative Analysis by Late Stage Development, H1 2016 19 Comparative Analysis by Clinical Stage Development, H1 2016 20 Comparative Analysis by Early Stage Development, H1 2016 21 Comparative Analysis by Unknown Stage Development, H1 2016 22 Products under Development by Companies, H1 2016 23 Products under Development by Companies, H1 2016 (Contd..1) 24 Products under Development by Companies, H1 2016 (Contd..2) 25 Products under Investigation by Universities/Institutes, H1 2016 26 Diabetic Macular Edema - Pipeline by Aciont Inc., H1 2016 27 Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016 28 Diabetic Macular Edema - Pipeline by Acucela Inc., H1 2016 29 Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H1 2016 30 Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2016 31 Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 32 Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H1 2016 33 Diabetic Macular Edema - Pipeline by Avalanche Biotechnologies, Inc., H1 2016 34 Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H1 2016 35 Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 36 Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016 37 Diabetic Macular Edema - Pipeline by EyeGene, Inc., H1 2016 38 Diabetic Macular Edema - Pipeline by Gene Signal International SA, H1 2016 39 Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2016 40 Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H1 2016 41 Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H1 2016 42 Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H1 2016 43 Diabetic Macular Edema - Pipeline by Mabion SA, H1 2016 44 Diabetic Macular Edema - Pipeline by MacuCLEAR, Inc., H1 2016 45 Diabetic Macular Edema - Pipeline by NicOx S.A., H1 2016 46 Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2016 47 Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H1 2016 48 Diabetic Macular Edema - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 49 Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 50 Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 51 Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H1 2016 52 Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 53 Diabetic Macular Edema - Pipeline by Shire Plc, H1 2016 54 Diabetic Macular Edema - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 55 Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2016 56 Diabetic Macular Edema - Pipeline by Verseon Corporation, H1 2016 57 Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2016 58 Assessment by Monotherapy Products, H1 2016 59 Assessment by Combination Products, H1 2016 60 Number of Products by Stage and Target, H1 2016 62 Number of Products by Stage and Mechanism of Action, H1 2016 64 Number of Products by Stage and Route of Administration, H1 2016 66 Number of Products by Stage and Molecule Type, H1 2016 68 Diabetic Macular Edema Therapeutics - Recent Pipeline Updates, H1 2016 145 Diabetic Macular Edema - Dormant Projects, H1 2016 181 Diabetic Macular Edema - Dormant Projects (Contd..1), H1 2016 182 Diabetic Macular Edema - Discontinued Products, H1 2016 183
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.